drugset

drugset / Trial / NCT01401322

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT01401322 ↗

Phase 2 Terminated 5 enrolled Stanford University Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

Time-to-Progression (TTP)

Timeline

Start: 2011-01
Primary completion: 2012-01
Completion: 2012-05

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	50 mg	Oral

Indications